Researchers have uncovered the role of cellular prion protein (PrPC) in Neurofibromatosis Type 2 (NF2) related tumors, offering hope to neuro-tumor patients.
Browsing: Disease Area > Brain and neurologic
A new assay test for five cancer-associated genes with the goal of aiding prediction of neuroblastoma in children has been reported.
The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients.
This review reports the results of application of short peptides in glioma therapy clinical trials, their rises and falls.
Researchers have uncovered a novel method of overriding the growth promoting effects of PTEN deletion and the answer is to inhibit another tumor suppressor gene.
Primary research to evaluate whether Recursive Partitioning Analysis or Graded Prognostic Assessment is more useful to clinicians.
The European Commission has approved dinutuximab beta for the treatment of high-risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy for these patients in Europe.
A comprehensive review article of the avaliable therapeutic strategies developed against malignant gliomas based on ‘actively targeted’ nanoparticles, it discusses challenges, mechanisms, clinical studies and treatment options